Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Tisotumab Vedotin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Tisotumab Vedotin||HuMax-TF-ADC|TF-011-MMAE||Tisotumab vedotin (HuMax-TF-ADC) is an antibody-drug conjugate consists of anti-tissue factor (TF) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces killing of tumor cells overexpressing tissue factor (PMID: 24371232, PMID: 31796521).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||Tisotumab Vedotin||Case Reports/Case Series||Actionable||In a Phase II trial, Tisotumab vedotin treatment resulted in prolonged stable disease in a patient with ovarian cancer (Journal of Clinical Oncology 33, no. 15_suppl (May 20 2015) 2570-2570; NCT02001623).||detail...|
|Unknown unknown||cervical cancer||not applicable||Tisotumab Vedotin||Phase Ib/II||Actionable||In a Phase I/II trial, Tisotumab vedotin treatment demonstrated safety and resulted in an investigator-assessed overall response rate of 24% (13/55, all partial responses), stable disease in 38% (21/55), and a median duration of response of 4.2 months in patients with previously treated recurrent or metastatic cervical cancer (PMID: 31796521; NCT02001623).||31796521|
|Unknown unknown||prostate cancer||not applicable||Tisotumab Vedotin||Case Reports/Case Series||Actionable||In a Phase II trial, Tisotumab vedotin treatment resulted in prolonged stable disease in 2 patients with prostate cancer (Journal of Clinical Oncology 33, no. 15_suppl (May 20 2015) 2570-2570; NCT02001623).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03245736||Phase II||Tisotumab Vedotin||Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.||Completed||USA||1|
|NCT03485209||Phase II||Tisotumab Vedotin||Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors||Recruiting||USA | CAN||5|
|NCT04697628||Phase III||Topotecan Gemcitabine Irinotecan Tisotumab Vedotin Pemetrexed Disodium Vinorelbine||Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301)||Recruiting||USA||0|
|NCT03657043||Phase II||Tisotumab Vedotin||A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)||Recruiting||USA||5|
|NCT03438396||Phase II||Tisotumab Vedotin||A Trial of Tisotumab Vedotin in Cervical Cancer||Active, not recruiting||USA||7|